The PADA-1 trial, conducted in 83 French hospitals, investigated the efficacy and safety of adjusting treatment based on rising ESR1 mutations in blood (bESR1mut) for patients with advanced ER-positive, HER2-negative breast cancer. Here, ESR1 is linked to breast cancer.